Related Tags >> Merck KgAA Ablynx development pact Gene Logic

Merck Serono News

Most Popular Merck Serono Story

Matuzumab in doubt after trial failure

August 29, 2007 — 6:59am ET

There's trouble at Merck Serono's program for Matuzumab, which is in development for colorectal cancer. Merck KGaA says it is "reconsidering" further development of the therapy after the... Read more...

Merck Serono Press Releases

Galapagos NV and Merck Serono Enter New Collaboration Agreements
Merck Serono's Kuvan(R) Recommended for European Approval
Merck Serono's Glucophage(R) Powder for Oral Solution in Sachet Receives Positive Opinion for Approval in Europe
ABLYNX AND MERCK SERONO ENTER INTO AN AGREEMENT TO CO-DISCOVER AND CO- DEVELOP NANOBODIES(R)
PRESS RELEASE: Merck Serono Exercises Option to Rigel's R763/AS703569 and Aurora Kinase Inhibitors in the Japanese Territory

Latest Headlines

Merck Serono, Theratechnologies ink $215M deal
October 29, 2008
Ablynx gains partner in $340M nanobody deal
September 4, 2008
Merck Serono, Bionomics partner on MS programs
June 18, 2008
ALSO NOTED: Pfizer to buy CovX; Florida commits $94M to Max Planck; Affymetrix buys USB; HGS touts animal trial results for ant
December 18, 2007
ALSO NOTED: Ventana and Roche forge confidentiality agreement; Rigel wins $3M payment; and much more...
November 14, 2007
DEALS: Solvay, Merck Serono ink deals with Gene Logic
August 30, 2007
Matuzumab in doubt after trial failure
August 29, 2007
Gene Logic takes fresh look at Merck KGaA drugs
August 24, 2007

Paid Research Reports